Integrative effects of transcutaneous auricular vagus nerve stimulation on esophageal motility and pharyngeal symptoms via vagal mechanisms in patients with laryngopharyngeal reflux disease

被引:0
|
作者
Huang, Yizhou [1 ]
Liu, Jie [2 ]
Lv, Chaolan [2 ]
Sun, Chenyu [3 ]
Meng, Muzi [4 ]
Lowe, Scott [5 ]
Yu, Yue [2 ]
机构
[1] PLA Navy Anqing Hosp, Dept Gastroenterol, Anqing, Anhui, Peoples R China
[2] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Gastroenterol, Div Life Sci & Med, Hefei, Anhui, Peoples R China
[3] Anhui Med Univ, Affiliated Hosp 2, Dept Gen Surg, Hefei, Anhui, Peoples R China
[4] Bronxcare Hlth Syst, New York, NY USA
[5] Kansas City Univ, Coll Osteopath Med, Kansas City, MO USA
关键词
vagus nerve stimulation; neuromodulation; autonomic function; heart rate variability; laryngopharyngeal reflux disease; SPHINCTER; THERAPY; ANXIETY;
D O I
10.3389/fnins.2024.1287809
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background and aim Laryngopharyngeal reflux disease (LPRD) is primarily characterized by discomfort in the pharynx and has limited treatment options. This research aimed to assess the efficacy of transcutaneous auricular vagus nerve stimulation (tVNS) in patients with LPRD and delve into the potential underlying mechanisms. Methods A total of 44 participants, diagnosed with LPRD were divided into two groups randomly. Twice-daily stimulation was delivered for 2 weeks for patients in experimental group, with stimulation ranging from 1.0 mA to 1.5 mA (n = 22), while the control group underwent sham tVNS (n = 22) with the same stimulation parameters and different anatomical location. The severity of symptoms and levels of anxiety and depression were monitored using questionnaires. High-resolution esophageal manometry data were collected, and the patients' autonomic function was assessed through heart rate variability analysis. Results There was a positive correlation between reflux symptom index (RSI) scores and low frequency/high frequency (LF/HF) ratio (r = 0.619; p < 0.001), Hamilton anxiety scale (HAMA) scores (r = 0.623; p < 0.001), and Hamilton depression scale (HAMD) scores (r = 0.593; p < 0.001). Compared to the pre-tVNS phase, RSI (p < 0.001), HAMA (p < 0.001), and HAMD (p < 0.001) scores were significantly reduced after 2 weeks of treatment. Additionally, the resting pressure of the upper esophageal sphincter (UESP; p < 0.05) and lower esophageal sphincter (LESP; p < 0.05) showed significant enhancement. Notably, tVNS led to an increase in root mean square of successive differences (RMSSD; p < 0.05) and high frequency (HF; p < 0.05) within heart rate variability compared to the pre-treatment baseline. Compared to the control group, RSI (p < 0.001), HAMA (p < 0.001), and HAMD (p < 0.001) scores in tVNS group were significantly lower at the end of treatment. Similarly, the resting pressure of UESP (p < 0.05) and LESP (p < 0.05) in tVNS group were significantly higher than that of control group. Notably, RMSSD (p < 0.05) and HF (p < 0.05) in tVNS group were significantly higher than that of control group. Conclusion This study demonstrated that tVNS as a therapeutic approach is effective in alleviating LPRD symptoms. Furthermore, it suggests that improvements in esophageal motility could be associated with vagus nerve-dependent mechanisms.
引用
收藏
页数:11
相关论文
共 22 条
  • [21] Immediate modulatory effects of transcutaneous vagus nerve stimulation on patients with Parkinson's disease: a crossover self-controlled fMRI study ( vol 16 , 1444703 , 2024)
    Fu, Chengwei
    Hou, Xiaoyan
    Zheng, Chunye
    Zhang, Yue
    Gao, Zhijie
    Yan, Zhaoxian
    Ye, Yongsong
    Liu, Bo
    FRONTIERS IN AGING NEUROSCIENCE, 2025, 17
  • [22] Anti-neuroinflammation effects of transcutaneous auricular vagus nerve stimulation against depression-like behaviors via hypothalamic α7nAchR/JAK2/STAT3/NF-κB pathway in rats exposed to chronic unpredictable mild stress
    Chen, Yu
    Zhang, Yue
    Wang, Junying
    Li, Shaoyuan
    Wang, Yifei
    Zhang, Zixuan
    Zhang, Jinling
    Xin, Chen
    Wang, Yu
    Rong, Peijing
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2634 - 2644